Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

viking therapeutics inc. - VKTX

VKTX

Close Chg Chg %
26.13 -0.48 -1.84%

Closed Market

25.65

-0.48 (1.84%)

Volume: 1.98M

Last Updated:

Mar 28, 2025, 4:00 PM EDT

Trade Now

Company Overview: viking therapeutics inc. - VKTX

VKTX Key Data

Open

$25.98

 Day Range

25.21 - 26.21

52 Week Range

24.41 - 82.00

 Market Cap

$2.93B

Shares Outstanding

112.25M

 Public Float

108.95M

Beta

0.90

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.01

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

4.02M

  

VKTX Performance

1 Week
 
 -11.40%
 
1 Month
 
 -11.15%
 
3 Months
 
 -37.68%
 
1 Year
 
 -68.72%
 
5 Years
 
 466.23%
 

VKTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About viking therapeutics inc. - VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

VKTX At a Glance

Viking Therapeutics, Inc.
9920 Pacific Heights Boulevard
San Diego, California 92121
Phone 1-858-704-4660 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -109,963,000.00
Sector Health Technology Employees 36
Fiscal Year-end 12 / 2025
View SEC Filings

VKTX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.10
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -23.152
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.00

VKTX Efficiency

Revenue/Employee N/A
Income Per Employee -3,054,527.778
Receivables Turnover N/A
Total Asset Turnover N/A

VKTX Liquidity

Current Ratio 33.094
Quick Ratio 33.094
Cash Ratio 32.926

VKTX Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -17.225
Return on Equity -17.899
Return on Total Capital -12.476
Return on Invested Capital -17.876

VKTX Capital Structure

Total Debt to Total Equity 0.127
Total Debt to Total Capital 0.127
Total Debt to Total Assets 0.123
Long-Term Debt to Equity 0.072
Long-Term Debt to Total Capital 0.071
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Viking Therapeutics Inc. - VKTX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
296.00K 291.00K 292.00K 346.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
296.00K 291.00K 292.00K 346.00K
Depreciation
296.00K 291.00K 292.00K 346.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+6.86% -1.69% +0.34% +18.49%
Gross Income
(296.00K) (291.00K) (292.00K) (346.00K)
Gross Income Growth
-6.86% +1.69% -0.34% -18.49%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
55.39M 70.06M 100.53M 150.57M
Research & Development
44.98M 54.23M 63.81M 101.64M
Other SG&A
10.40M 15.83M 36.73M 48.93M
SGA Growth
+30.67% +26.50% +43.49% +49.77%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(55.68M) (70.36M) (100.83M) (150.92M)
Non Operating Income/Expense
710.00K 1.55M 15.02M 41.05M
Non-Operating Interest Income
703.00K 1.59M 15.02M 40.94M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.00K 59.00K 88.00K 94.00K
Interest Expense Growth
-83.02% +227.78% +49.15% +6.82%
Gross Interest Expense
18.00K 59.00K 88.00K 94.00K
Interest Capitalized
- - - -
-
Pretax Income
(54.99M) (68.87M) (85.89M) (109.96M)
Pretax Income Growth
-39.23% -25.24% -24.73% -28.02%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(54.99M) (68.87M) (85.89M) (109.96M)
Minority Interest Expense
- - - -
-
Net Income
(54.99M) (68.87M) (85.89M) (109.96M)
Net Income Growth
-39.23% -25.24% -24.73% -28.02%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(54.99M) (68.87M) (85.89M) (109.96M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(54.99M) (68.87M) (85.89M) (109.96M)
EPS (Basic)
-0.7123 -0.8963 -0.9104 -1.0085
EPS (Basic) Growth
-30.94% -25.83% -1.57% -10.78%
Basic Shares Outstanding
77.20M 76.83M 94.35M 109.04M
EPS (Diluted)
-0.7123 -0.8963 -0.9104 -1.0085
EPS (Diluted) Growth
-30.94% -25.83% -1.57% -10.78%
Diluted Shares Outstanding
77.20M 76.83M 94.35M 109.04M
EBITDA
(55.39M) (70.06M) (100.53M) (150.57M)
EBITDA Growth
-30.67% -26.50% -43.49% -49.77%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 99.125
Number of Ratings 17 Current Quarters Estimate -0.333
FY Report Date 03 / 2025 Current Year's Estimate -1.595
Last Quarter’s Earnings -0.32 Median PE on CY Estimate N/A
Year Ago Earnings -1.01 Next Fiscal Year Estimate -2.159
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 17 16
Mean Estimate -0.33 -0.38 -1.60 -2.16
High Estimates -0.16 -0.19 -0.98 -1.53
Low Estimate -0.44 -0.47 -2.16 -3.10
Coefficient of Variance -20.86 -19.35 -18.63 -19.98

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 14
OVERWEIGHT 0 0 0
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Viking Therapeutics Inc. - VKTX

Date Name Shares Transaction Value
Aug 23, 2024 J. Matthew Singleton Director 10,300 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 23, 2024 Brian Lian President & CEO; Director 2,355,927 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.77 per share 18,305,552.79
Aug 23, 2024 J. Matthew Singleton Director 9,500 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.72 per share 662,340.00
Aug 23, 2024 J. Matthew Singleton Director 15,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.19 per share 18,088.00
Aug 23, 2024 Brian Lian President & CEO; Director 2,354,927 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.9 per share 164,609,397.30
Aug 23, 2024 Brian Lian President & CEO; Director 231,130 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Brian Lian President & CEO; Director 2,354,927 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $67.12 per share 158,062,700.24
Aug 20, 2024 J. Matthew Singleton Director 15,444 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $61.86 per share 955,365.84
Aug 20, 2024 J. Matthew Singleton Director 13,389 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $63.15 per share 845,515.35
Aug 20, 2024 J. Matthew Singleton Director 11,001 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.1 per share 705,164.10
Aug 20, 2024 J. Matthew Singleton Director 9,500 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.88 per share 616,360.00
Aug 20, 2024 J. Matthew Singleton Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Brian Lian President & CEO; Director 232,130 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 187,052 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.71 per share 10,981,822.92
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 187,552 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.71 per share 10,823,625.92
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 190,526 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $56.96 per share 10,852,360.96
Aug 1, 2024 Gregory S. Zante Chief Financial Officer 181,521 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2024 Marianne Mancini Chief Operating Officer 358,508 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2024 Marianne Mancini Chief Operating Officer 380,175 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 1, 2024 Marianne Mancini Chief Operating Officer 362,149 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $57.82 per share 20,939,455.18

Viking Therapeutics Inc. in the News